| |
Bibliografía sobre drogas inteligentes
Tomada de
Smart Drugs I y
Smart Drugs II, de Dean, Morgenthaler y Fowkes (http://www.ceri.com)
Referencias generales sobre nootrópicos
Anderson, K., Anderson, L. Orphan Drugs.
Los Angeles, CA: The Body Press,
1987,
p.
132.
Bartus, R.T., Dean R.L.
3d,
Sherman, K.A.,
Friedman, E., Beer, B. "Profound Effects of Combining Choline and
Piracetam on Memory Enhancement and Cholinergic Function in Aged Rats."
Neurobiology of Aging.
1981,
Vol.
2,
pp.
105-11.
Berga,
P., Beckett,
P.R., Roberts, D.J., Llenas, J., Massingham, R. "Synergistic
Interactions Between Piracetam and Dihydro-ergocristine in Some Animal
Models of Cerebral Hypoxia and Ischaemia."
Arzneimittelforschung. 1986, 36 (9),
pp.
1314-20.
Ferris,
S.U.,
et
al.
"Combination of Choline/Piracetam in the Treatment of Senile Dementia."
Psychopharmacology Bulletin.
1982,
Vol.
18,
pp.
94-98.
Flood, J.F.,
Smith,
G.E., Cherkin, A. "Memory Retention: Potentiation of Cholinergic Drug
Combinations in Mice."
Neurobiology of Aging.
1983, 4 (1)
pp.
37-43.
Flood, J.F.,
Smith,
G.E., Cherkin, A. "Memory Enhancement: Supra-Additive Effect of
Subcutaneous Cholinergic Drug Combinations in Mice." Psychopharmacology.
1985, 86
(1-2)
pp.
61-7.
Flood, J.F.,
Cherkin, A. "Effect of Acute Arecoline, Tacrine and Arecoline
+
Tacrine
Post-Training Administration on Retention in Old Mice." Neurobiology of
Aging.
1988, 9 (1)
pp.
5-8.
Flood, J.F., Smith, G.E., Cherkin, A.
"Two-Drug Combinations of Memory Enhancers: Effect of Dose Ratio Upon
Potency and Therapeutic Window, in Mice."
Life
Science.
1988,42 (21)
pp.
2145-54.
Friedman, E., Sherman, K.A., Ferris, S.H.,
Reisberg,
B., Bartus,
R.T., Schneck, M.K. "Clinical Response to Choline Plus Piracetam in
Senile Dementia: Relation to Red-Cell Choline Levels." The New England
Journal of Medicine.
1981, 304,
No.
24,
pp.
1490-91.
Fuller, R.B. Synergetics. New York:
Macmillan Publishing,
1975.
Heiby, W. The Reverse Effect. Deerfield,
IL: Mediscience.
Pepeu, G., Spignoli, G., Giovannini, M.G.,
Magnani, M. "The Relationship Between the Behavioral Effects of
Cognition-Enhancing Drugs and Brain Acetylcholine. Nootropic Drugs and
Brain Acetylcholine." Pharmacopsychiatry. 1989, 22 Supplement 2, pp.
116-9.
Poschel, B.P.H., Marriott, J.G., Gluckman,
M.I. "Pharmacology of the Cognition Activator Pramiracetam (CI-879)."
Drugs Under Experimental and Clinical Research. 1983, vol. 9(12), pp.
853-71.
Piracetam
Anderson, K., Anderson, L. Orphan Drugs.
Los Angeles, CA: The Body Press,
1987,
p.
169.
Bartus, R.T., Dean R.L.
3d,
Sherman, K.A.,
Friedman, E., Beer, B. "Profound Effects of Combining Choline and
Piracetam on Memory Enhancement and Cholinergic Function in Aged Rats."
Neurobiology of Aging.
1981,
Vol.
2,
pp.
105-11.
Buresova, O., Bures, J. "Piracetam-Induced
Facilitation of Interhemispheric Transfer of Visual Information in
Rats.H Psychopharmacologia.
1976,
Vol.
46,
pp.
93-102.
Bylinsky, G. "Medicine's Next Marvel: The
Memory Pill." Fortune. January
20, 1986,
pp.
68-72.
Chase, C.H.,
Schmitt,
R.L.,
Rüssel,
G.,
Tallal, P. "A New Chemotherapeutic Investigation: Piracetam Effects on
Dyslexia."
Annals
of Dyslexia.
1984,
Vol.
34,
pp.
29-48.
Conners,
C.K., Blouin,
A.G., Winglee, M., Lougee, L., O'Donnell, D., Smith, A. "Piracetam and
Event-Related Potentials in Dyslexic Children." Psychopharmacology
Bulletin.
1984,
Vol.
20,
pp.
667-73.
Dimond, S.J., Browers, E.Y.M. "Increase in
the Power of Human Memory in Normal Man Through the Use of Drugs."
Psychopharmacology.
1976,
Vol.
49,
pp.
307-9.
Dilanni, M.,
Wilsher,
C.R., Blank,
M.S.,
Conners,
C.K., Chase,
C.H.,
Funkenstein, H.H., Helfgott, E., Holmes, J.H., Lougee, L.,
Marietta,
G.J.,
Milewski,
J.,
Pirazzolo, F.J.,
Rudel, R.G., Tallal, P. "The Effects
of
Piracetam in
Children with Dyslexia."
Journal
of Clinical
Psychopharmacology.
1985,
Vol.
5,
pp.
272-8.
Donaldson, T. "Therapies to Improve
Memory." Anti-Aging News.
1984,
No.
4,
pp.
13-21.
Ferris, S.H.,
et
al.
"Combination of Choline/Piracetam in the Treatment of Senile Dementia."
Psychopharmacology Bulletin.
1982,
Vol.
18,
pp.
94-8.
Friedman, E., Sherman, K.A., Ferris, S.H.,
Reisberg,
B., Bartus,
R.T., Schneck, M.K. "Clinical Response to Choline Plus
Piracetam
in Senile
Dementia: Relation to Red-Cell Choline Levels." The New England Journal
of Medicine.
1981, 304,
No.
24,
pp.
1490-1.
Giurgea, C.E. "The 'Nootropic' Approach to
the Pharmacology of the Integrative Activity of the Brain." Conditional
Reflex.
1973,
Vol.
8,
No.
2,
pp.
108-15.
Giurgea, C.E. "A Drug for the Mind."
Chemtech. June
1980,
pp.
360-65.
Giurgea, C.E., Salama, M. "Nootropic Drugs."
Progress in
Neuro-psychopharmacology.
1977,
Vol.
1,
pp.
235-47.
Kent, S.
"Piracetam
Increases Brain Energy." Anti-Aging News.
1981,
Vol.
2,
No.
10,
pp.
65-69.
Mindus, P., Cronholm, B., Levander, S.E.,
Schalling,
D. "Piracetam-Induced
Improvement of Mental Performance: A Controlled Study on Normally Aging
Individuals." ACTA Psychiatrica Scandinavia.
1976,
Vol.
54,
pp.
150-60.
Mondadori, C, Classen, W., Borkowski, J.,
Ducret, T., Buerki, H.,
Schade,
A. "Effects
of Oxiracetam on Learning and Memory in Animals: Comparison with
Piracetam."
Clinical Neuropharmacology.
1986,
Vol.
9,
Supplement
13.
New York: Raven Press, pp. S27-S37.
Nickerson,
V.J.,
Wolthius, O.L.
"Effect of the Acquisition-Enhancing Drug
Piracetam
on Rat
Cerebral Energy Metabolism Comparison with
Naftidrofuryl
and
Methamphetamine."
Biochemical Pharmacology.
1976,
Vol.
25,
pp.
2241-4.
Parducz, A. "Depletion of Synaptic Vesicle
Lipids in Stimulated Cholinergic Nerve Terminals." Alzheimer's Disease:
Advances in Basic Research and Therapies. Proceedings of the Third
Meeting of the International Study Group of the Treatment of Memory
Disorders Associated with Aging. Zurich, Switzerland, 1984, pp. 217-26.
Pearson, D., Shaw, S. Durk Pearson & Sandy
Shaw's Life Extension Newsletter. October 1988, Vol 1, Number 8, p. 65.
Pellegata, R., et al. "Cyclic Gaba-Gabob
Analogues." Presented at VI International meeting of the International
Society For Neuro-chemistry, Copenhagen, August 21-26, 1977.
Pelton, R., Pelton, T.C. Mind Food & Smart
Pills. New York: Double-day, 1989.
Pepeu, G., and Spignoli, G. Neurochemical
Actions of "Nootropic Drugs". Advances in Neurology. Vol. 51:
Alzheimer's Disease. New York: Raven Press, Ltd., 1990.
Pilch, H., Muller, W.E. "Piracetam
Elevates Muscarinic Cholinergic Receptor Density in the Frontal Cortex
of Aged But Not of Young Mice." Psychopharmacology. 1988, 94, pp. 74-8.
Poschel, B.P.H. "New Pharmacologic
Perspectives on Nootropic Drugs." Handbook of Psychopharmacology. 1988,
pp. 11-18, pp. 24-5.
Stegink, A.J. "The Clinical Use of
Piracetam, a New Nootropic Drug." Arzneimittelforschung. 1972, Vol. 22,
No. 6, pp. 975-7.
U.C.B. Laboratories, Pharmaceutical
Division. "Basic Scientific and Clinical Data of Nootropil." Brussels,
Belgium: U.C.B. Laboratories, 1977.
Wilsher, C.R. "Piracetam and Dyslexia:
Effects on Reading Tests." Journal of Clinical Psychopharmacology. 1987,
Vol. 7, No. 4, pp. 230-7.
Wurtman, R.J., Magil, S.G., Reinstein, D.K.
"Piracetam Diminishes Hippocampal Acetylcholine Levels in Rats." Life
Science. 1981, Vol. 28, pp. 1091-3.
Zhang, S., et al. "Effects of Cerebral
GABA Level on Learning and Memory." Pharmacologics Sinica. 1989 10(1):
pp. 10-2.
Piracetam
Chaudhry
HR, Najam
N,
De
Mahieu C, Raza A, Ahmad
N.
Clinical use of piracetam in epileptic
patients.
Curr TherRes Clin Exp
52(3): 355-60,1992.
Fioravanti M, Bergamasco B, Bocola
V,
et
al..
A multicentre, double-blind, controlled
study of piracetam vs. placebo in geriatric patients with nonvascular
mild-moderate impairment in cognition.
New Trends in Clinical Neuropharmacology
(Italy)
5(1): 27-34,1991.
Mindus
P, Cronholm B, Levander SE, and
Schalling
D. Piracetam-induced study on normally
aging individuals.
Acta Psychiat Scand
54:150-60,1976.
Schaffler
K and Klausnitzer
W. Randomized
placebo-controlled double-blind crossover study on antihypoxidotic
effects of piracetam using psychophysiological measures in healthy
volunteers.
Arzneim-Forsch
38(2): 288-91,1988.
Schmidt U, Brendemuhl D,
Engels
K,
et
al..
Arbeits und Forschungsgemeinschaft
fur
Strassenverkehr und Verkehrssicherheit.
Pharmacopsychiatry
(Germany)
24(4): 121-26,
July
1991.
Aniracetam
Cumin,
R.,
Bandle,
E.F., Gamzu,
E., Haefely, W.E. "Effects of the Novel Compound Aniracetam (RO13-5057)
Upon Impaired Learning and Memory in
Rodents."
Psychopharmacology.
1982,
Vol.
78,
pp.
104-11.
Foltyn, P., Lucker, P.W., Schnitker, J.,
Wetzelsberger,
N.
"A Test Model for Cerebrally-Active Drugs
as Demonstrated by the Example of the New Substance Aniracetam"
Arzneimittelforschung.
1983, 33 (6)
pp.
865-7.
Gamzu, E.,
et
al.
"Pharmacological Protection Against Memory Retrieval Deficits as a
Method of Discovering New Therapeutic Agents."
Alzheimer's and Parkinson's Disease: Strategies in
Research and Development.
Advances in Behavioral Biology, vol.
29,
New York,
Plenum Press,
1986.
Pelton, R., Pelton, T.C.
Mind Food
&
Smart Pills.
New York: Double-day,
1989.
Saletu, B., Gnraberger, J.,
Linzmayer,
L.
"Quantitative
EEG
and
Psychometric Analyses in Assessing CNS-Activity of RO
13-5057—a
Cerebral Insufficiency Improver."
Methods and Findings in Experimental Clinical
Pharmacology.
1980,2 (5)
pp.
269-85.
Saletu, B., Gnraberger, J. "The Hypoxia
Model in Human Psychopharmacology: Neurophysiological and Psychometric
Studies with Aniracetam
I.V."
Human Neurobiology.
1984, 3 (3)
pp.
171-81.
Fipexide
Bompani, R., Scali G. "Fipexide, an
Effective Cognition Activator in the Elderly: a Placebo-Controlled,
Double-Blind Clinical Trial."
Current Medical Research and Opinion.
1986, 10 (2) pp. 99-106.
Rolandi, E., Franceschini, R., Marabini,
A., Messina, V., Bongera, P., Barreca, T. "Pituitary Secretion After
Administration of a New Cerebroactive Drug, Fipexide."
British Journal of Clinical Pharmacology.
1984, 18 (2) pp. 236-9.
Serra, G., Collu, M., Martellotta, M.C.,
Forgione, A., Fratta, W. "Effect of Fipexide on Passive Avoidance
Behavior in Rats."
Pharmacological Research.
1989, 21(5) pp. 603-8.
Valzelli, L., Baiguerra, G., Giraud,
O.
"Difference in Learning and Retention by
Albino Swiss Mice. Part III. Effect of Some Brain Stimulants."
Methods and Findings in Experimental and Clinical
Pharmacology.
1986, 8(6) pp. 337-41.
Vinpocetine
DeNoble,
V.J.,
Repetti, S.J.,
Gelpke,
L.W.,
Wood, L.M.,
Keim,
K.L. "Vinpocetine:
Nootropic Effects on Scopolamine-Induced and Hypoxia-Induced Retrieval
Deficits of a Step-Through Passive Avoidance Response in Rats."
Pharmacology Biochemistry
&
Behavior.
1986,
Vol.
24,
pp.
1123-8.
Otomo, E., Atarashi, J., Araki, G., Ito,
E., Omae, T., Kuzuya,
F.,
Nukada, T.,
Ebi, O. "Comparison of Vinpocetine with Ifen-prodil Tartrate and
Dihydroergotoxine Mesylate Treatment and Results of Long-Term Treatment
with Vinpocetine."
Current Therapeutic Research.
1985,
Vol.
37,
No.
5,
pp.
811-21.
Pelton, R., Pelton, T.C. Mind Food
&
Smart Pills.
New York: Double-day,
1989.
Subhan, Z., Hindmarch, I.
"Psychopharmacological Effects of Vinpocetine in Normal Healthy
Deprenyl
Carillo MC, Kanai S, Nohubo M,
et al
(-)-Deprenyl induced activities of both
superoxide dismutase and catalase in young male rats.
Life Sci
48: 517,1991.
Falsaperla A, Monici Preti PA and Oliani
C. Selegiline versus oxiracetam in patients with Alzheimer-type
dementia.
Clin Ther
12(5): 376-84, Sep-Oct 1990.
Finali G, Piccirilli M, Oliani C and
Piccinin GL. Alzheimer-type dementia and verbal memory performances:
influence of selegiline therapy.
Ital J Neurol Sci
13(2): 141-8, March 1992.
Finali G, Piccirilli M, Oliani C and
Piccinin GL. L-deprenyl therapy improves verbal memory in amnesic
Alzheimer patients.
Clin Neuropharmacol
(USA) 14(6): 523-36,1991.
Goad DL, Davis CM, Liem
P, Fuselier CC, McCormack JR
and Olsen KM. The use of selegiline in Alzheimer's patients with
behavior problems.
J Clin Psychiatry
52(8): 342-5, August 1991. Also see
comments,
J Clin Psychiatry
53(3): 101-2, March 1992.
Knoll J. (-)Deprenyl-medicalion: A
strategy to modulate the age-related decline of the striatal
dopaminergic system.
J Am Geriatr Soc
40(8): 839-47, August 1992.
Knoll J. Extension of lifespan of rats by
long-term (-)deprenyl treatment.
Mount Sinai J Med
55: 67-74,1988.
Knoll J. Pharmacological basis of the
therapeutic effect of deprenyl in age-related neurological diseases.
MedResRev
(United States) 12(5): 505-24, September
1992.
Knoll J. Pharmacological basis of the
therapeutic effect of deprenyl in age-related neurological diseases.
Med Res Rev
(United States) 12(5): 505-24, Sept 1992.
Knoll J. The pharmacology of selegiline
((-)deprenyl). New aspects.
Acta Neurol Scand
126:83-91,1989.
Knoll J. The pharmacology of selegiline
(-)deprenyl: New aspects.
Acta Neurol Scand
126: 83,1989.
Knoll J. The possible mechanism of action
of (-)deprenyl in Parkinson's disease.
Journal of Neural Transmission
43: 239-44,1978.
Knoll J. The striatal dopamine dependency
of lifespan in male rats. Longevity study with (-)deprenyl.
Mechanisms of Aging and Development
46: 237-62,1988.
Knoll J, Yen TT and Dallo J. Long-lasting,
true aphrodisiac effect of (-)deprenyl in sluggish old male rats.
Mod Probl Pharmacopsychiat
19:135-53,1983.
Lees AJ. Selegiline hydrochloride and
cognition.
Acta Neurol Scand Suppl
136: 91-4, 1991.
Letters to the Editor on deprenyl in
Parkinson's disease,
The New England Journal of Medicine
322:1526-7, 24 May 1990.
Mangoni A, Grassi MP, Frattola L, Piolti
R, Bassi S, Motta A, Marcone A and Smirne S. Effects of a MAO-B
inhibitor in the treatment of Alzheimer's disease.
Eur Neurol
(Switzerland) 31(2): 100-7,1991.
Martini E, Pataky I, Szilagyi K and Venter
V. Brief information on an
early phase-II-study with deprenyl in demented patients.
Pharmacopsychiatry
(Germany, Federal Republic of) 20(6):
256-257,1987.
Milgram NW,
et al.
Maintenance on L-deprenyl prolongs life in
aged male rats.
Life Sciences
47: 415-20,1990.
Monteverde A, Gnemmi
P, Rossi
F, Monteverde A and Finali
GC. Selegiline in the treatment of mild to moderate Alzheimer-type
dementia.
Clin Ther
12(4): 315-22, Jul-Aug 1990.
Piccinin GL, Finali G and Piccirilli M.
Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.
Clin Neuropharmacol
13(2): 147-63, April 1990.
Sabelli HC. Rapid treatment of depression
with selegiline-phenylalanine combination
Journal of Clinical Psychiatry
53(3): 137, March 1991.
Schneider LS, Pollock VE, Zemansky MF,
Gleason RP, Palmer R and Sloane RB. A pilot study of low-dose L-deprenyl
in Alzheimer's disease.
J Geriatr Psychiatry Neurol
(USA) 4(3): 143-8,1991.
Tariot
PN,
et aL
L-Deprenyl in Alzheimer's disease:
Preliminary evidence for behavioral change with monoamine oxidase B
inhibition.
Archives
of General Psychiatry
44: 427-33, May 1987.
Centrofenoxina
Anderson, K., Anderson, L. Orphan Drugs.
Los Angeles, CA: The Body Press,
1987,
p.
132.
Dowson, J.H., Wilton-Cox, H. "The Effect
of Drugs on Neuronal Lipopigment" Lipofuscin—1987:
State
of the Art. Nagy (ed), Amsterdam: Elsevier Science Publishers,
1988,
pp.
271-88.
Gedye, J.L., Exton-Smith,
A.N.,
Wedgewood, J.
"A Method for Measuring Mental Performance in the Elderly and its Use in
a Pilot Clinical Trial of Meclofenoxate in Organic Dementia"
Age
and Ageing.
1972, 1,
pp.
74-80.
Hochschild,
R. "Effect of
Dimethylaminoethyl p-Chlorophenoxy-acetate on the Life Span of Male
Swiss Webster Albino Mice.
"
Experimental
Gerontology.
1973,
Vol.
8,
pp.
177-83.
Jarvik, L.F. "The Aging Nervous System:
Clinical Aspects." Aging. New York: Raven Press,
1975,
Vol.
1,
pp.
1-9.
Marcer,
D., Hopkins,
S.M. "The Differential Effects of Meclofenoxate on Memory Loss in the
Elderly." Age and Ageing.
1977,
Vol.
6,
pp.
123-31.
Nandy, K. "Aging Neurons and
Pharmacological Agents."
Aging.
New York: Raven Press,
1983,
Vol.
21,
pp.
401-15.
Nandy, K. "Lipofuscinogenesis in Mice
Early Treated with Centro-phenoxine." Mechanisms of Aging and
Development.
1978,
Vol.
8,
pp.
131-8.
Nandy, K., Bourne, G.H. "Effect of
Centrophenoxine on the Lipofuscin Pigments of the Neurones of Senile
Guinea Pigs." Nature.
1966,
Vol.
210,
pp.
313-4.
Nandy, K., Mostofsky,
D.I.,
Idrobo,
F.,
Blatt,
L., Nandy, S.
"Experimental Manipulations of Lipofuscin Formation in Aging Mammals."
Lipofuscin—1987:
State
of the Art. Nagy, I. (ed), Amsterdam: Elsevier Science Publishers,
1988,
pp.
289-304.
Pearson, D., Shaw, S. Life Extension: A
Practical Scientific Approach. New York: Warner Books,
1982.
Pelton, R., Pelton, T.C. Mind Food
&
Smart Pills.
New York: Double-day,
1989.
Riga, S., Riga, D. "Effects of
Centrophenoxine on the Lipofuscin Pigments of the Nervous System of Old
Rats."
Brain
Research.
1974,
Vol.
72,
pp.
265-75.
Zuckerman, B., Barrett, K. "Effects of PC
A and DMAE on the Nematode Caenorhabditis Briggsae."
Experimental Aging Research.
1978, 4 (2)
pp.
133-9.
Deanol (DMAE)
Anderson, K., Anderson, L. Orphan Drugs.
Los Angeles, CA: The Body Press,
1987,
p.
69.
Ceder, G., et al. "Effects of
2-Dimethylaminoethanol (Deanol) on the Metabolism of Choline in Plasma."
Journal of Neurochemistry.
1978,
Vol. 30,
pp.
1293-96.
Hochschild,
R. "Effect of
Dimethylaminoethyl p-Chlorophenoxy-acetate on the Life Span of Male
Swiss Webster Albino Mice."
Experimental Gerontology.
1973,
Vol.8, pp.
177-83.
Honegger, C, Honegger, R. "Occurrence and
Quantitative Determination of 2-Dimethylaminoethanol in Animal Tissue
Extracts." Nature.
1959,
Vol.
184,
pp.
550-52.
Murphree, H.B., et al. "The Stimulant
Effect of 2-Dimethylaminoethanol (Deanol) in Human Volunteer Subjects."
Clinical Pharmacology and Therapeutics.
1960,
Vol.
1,
pp.
303-10.
Oettinger, L. "The Use of Deanol in the
Treatment of Disorders of Behavior in Children." The Journal of
Pediatrics.
1958,
Vol.
3,
pp.
671-5.
Osvaldo, R. "2-Dimethylaminoethanol (Deanol):
A Brief Review of Its Clinical Efficacy and Postulated Mechanism of
Action."
Current Therapeutic Research.
1974,
Vol.
16,
No.
11,
pp.
1238-42.
Pearson, D., Shaw, S. Life Extension: A
Practical Scientific Approach. New York: Warner Books,
1982.
Pelton, R., Pelton, T.C. Mind Food
&
Smart Pills.
New York: Double-day,
1989.
Pfeiffer,
C.C.
"Parasympathetic Neurohumors. Possible Precursors and Effect on
Behavior."
International Review of Neurobiology.
1959,
pp.
195-244.
Pfeiffer,
C.C, et al.
"Stimulant Effect of 2-Dimethyl-l-aminoethanol: Possible Precursor of
Brain Acetylcholine." Science.
1957,
Vol.
126,
pp.
610-1.
Zuckerman, B., Barrett, K. "Effects of PCA
and DMAE on the Nematode Caenorhabditis Briggsae."
Experimental Aging Research.
1978, 4 (2)
pp.
133-9.
Ginkgo
biloba
Allard,
M. "Treatment
of Old Age Disorders with Ginkgo Biloba Extract."
La Presse
Medicale.
1986,
Vol.
15,
No.
31,
p.
1540.
Auguet,
M.,
Delaflotte,
S.,
Hellegouarch, A., Clostre,
F. "Bases Pharmacologiques
de l'Impact
Vasculaire
de l'Extrait de
Ginkgo
Biloba," La
Presse Médicale.
1986,
Vol.
15,
No.
31,
p.
1524.
Funfgeld, E.W. "A
Natural and
Broad Spectrum Nootropic
Substance
for Treatment
of SDAT—the Ginkgo Biloba Extract.
"
Progress in
Clinical and Biological Research.
1989, 317,
pp.
1247-60.
Gebner,
B., Voelp,
A.,
Klasser,
M. "Study of
the Long-term Action of a Ginkgo Biloba Extract on Vigilance and Mental
Performance as Determined by Means of Quantitative Pharmaco-EEG and
Psychometric Measurements."
Arzneimittelforschung. 1985,
Vol.
35,
No.
9,
pp.
1459-65.
Hindmarch, I. "Activity of Ginkgo Biloba
Extract on Short-term Memory."
La Presse
Medicale.
1986,
Vol.
15,
No.
31,
p.
1562, 1592.
Pelton, R., Pelton, T.C. Mind Food
&
Smart Pills.
New York: Double-day,
1989.
Schaffler,
K., Reeh, P.
"Long-term Drug Administration Effects of Ginkgo Biloba on the
Performance of Healthy Subjects Exposed to Hypoxia." From
Agnoli,
J., Effects
of Ginkgo Biloba Extracts on Organic Cerebral Impairment. Eurotext Ltd.,
1985,
pp.
77-84.
Taillandier,
J., Ammar,
A., Rabourdin, J.P., Ribeyre, J.P., Pichon, J., Niddam,
S.,
Pierart,
H.
"Traitement des
Troubles
du
Viellisse-ment Cerebral par
l'Extract de
Ginkgo
Biloba."
La Presse
Medicale.
1986,
Vol.
15,
No.
31.
p.
1583.
Warburton,
D.M.
"Clinical
Psychopharmacology of Ginkgo Biloba Extract."
La Presse
Medicale.
1986,
Vol.
15,
No.
31,
p.
1595.
Hydergina
Branconnier, R. "The Efficacy of the
Cerebral Metabolic Enhancers inn the Treatment of Senile Dementia."
Psychopharmacology Bulletin. 1983, 19(2), pp. 212-20.
Copeland, R.L., Jr., Bhattacharyya, A.K.,
Aulakh, C.S., Pradhan, S.N. "Behavioral and Neurochemical Effects of
Hydergine in Rats". Archives of International Pharmacodynamics. 1981,
Vol. 252, pp. 113-23.
Emmenegger, H., Meier-Ruge, W. "The
Actions of Hydergine on the Brain." Pharmacology. 1968, Vol. 1, pp.
65-78.
Exton-Smith, A.N.,
et al.
"Clinical Experience with Ergot
Alkaloids." Aging. New York: Raven Press, 1983, Vol. 23, p. 323.
Fanchamps, A. "Dihydroergotoxine in Senile
Cerebral Insufficiency." Aging. New York: Raven Press, 1983, Vol. 23,
pp. 311-22.
Hindmarch, I., Parrott, A.C., Lanza, M.
"The Effects of an Ergot Alkaloid Derivative (Hydergine) on Aspects of
Psychomotor Performance, Arousal, and Cognitive Processing Ability." The
Journal of Clinical Pharmacology. November-December 1979, pp. 726-31.
Hollister, L.E. "Ergoloid Mesylates and
the Treatment of Senile Dementias. " Perspectives in
Psychopharmacology: A Collection of Papers in Honor of Earl Usdin. 1988,
New York, Alan R. Liss, pp. 613-20.
Hughes, J.R., Williams, J.G., Currier,
R.D. "An Ergot Alkaloid Preparation (Hydergine) in the Treatment of
Dementia: A Critical Review of the Clinical Literature." Journal of the
American Geriatrics Society. 1976, Vol. 24, pp. 490-97.
Pearson, D., Shaw, S. Life Extension: A
Practical Scientific Approach. New York: Warner Books, 1982.
Pelton, R., Pelton, T.C. Mind Food & Smart
Pills. New York: Double-day, 1989.
Rao, D.B., Norris, J.R. "A Double-Blind
Investigation of Hydergine in the Treatment of Cerebrovascular
Insufficiency in the Elderly." Johns Hopkins Medical Journal. 1971, Vol.
130, pp. 317-23.
Spiegel, R., Huber, F., Koberle, S. "A
Controlled Long-Term Study with Ergoloid Mesylates (Hydergine) in
Healthy, Elderly Volunteers: Results After Three Years." Journal of the
Geriatrics Society. 1983, Vol. 31, No. 9, pp. 549-55.
Thompson, T.L. II, Filley, CM., Mitchell,
W.D., et al. "Lack of Efficacy of Hydergine in Patients with Alzheimer's
Disease." New England Journal of Medicine. 1990, 323: pp. 445-8.
Weil, C, ed. "Pharmacology and Clinical
Pharmacology of Hydergine." Handbook of Experimental Pharmacology. New
York: Springer-Verlag, 1978.
Yesavage, J.A., Hollister, L.E., Burian,
E. "Dihydroergotoxine: 6-Mg versus 3-Mg Dosage in the Treatment of
Senile Dementia. Preliminary Report." Journal of the American Geriatrics
Society. 1979, Vol. 27, No. 2, pp. 80-82.
Yoshikawa, M., Hirai, S., Aizawa, T.,
Kuroiwa, Y., Goto, F., Some, I., Toyokura, Y.,
Yamamura, H., Iwasaki, Y. "A Dose-Response
Study with Dihydroergotoxine Mesylate in Cerebrovascular Disturbances."
Journal of the American Geriatrics Society. 1983, Vol. 31, No. 1, pp.
1-7.
Vasopresina
de Wied,
D., van
Wimersma Greidanus, T.B., Bohus, B., Urban, I., Gispen, W.H.
"Vasopressin and Memory Consolidation." Perspectives in Brain Research.
New York: Elsevier Scientific Publishing,
1975.
Gold, P.W., Weingartner, H.,
Ballenger,
J.C.,
Goodwin, F.K., Post, R.M. "Effects of l-Desamo-8-Arginine Vasopressin on
Behavior and Cognition in Primary Affective Disorders." The Lancet.
November
10, 1979,
pp.
992-94.
Laczi,
F.,
Valkusz, Z.,
Laszlo, F.A., Wagner, A., Jardanhazy, T., Szasz, A., Szilard, J.,
Telegdy, G. "Effects of Lysine-Vasopressin and
l-Deanüno-8-D-Arginine-Vasopressin
on Memory in Healthy Individuals and Diabetes Insipidus Patients."
Psychoneuroendocrinology.
1982,
Vol.
7,
No.
2,
pp.
185-92.
Legros, J.J., Gilot, P.,
Seron,
X.,
Ciaessens,
J.,
Adam, A., Moeglen, J.M.,
Audibert,
A., Berchier,
P. "Influence of Vasopressin on Learning and Memory." The Lancet.
January
7, 1978,
pp.
41-42.
Oliveros,
J.C.,
Jandali,
M.K.,
Timsit-Berthier, M., Remy, R., Beng-hezal, A.,
Audibert,
A., Moeglen,
J.M. "Vasopressin in Amnesia." The Lancet. January
7, 1978,
p.
42.
Pearson, D., Shaw, S. Life Extension: A
Practical Scientific Approach. New York: Warner Books,
1982.
Pelton, R., Pelton, T.C. Mind Food
&
Smart Pills.
New York: Double-day,
1989.
|
|
